Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This chapter covers various dermatological drugs, cosmetics, and topical agents, focusing on the properties and uses of propolis, but does not present new clinical findings.

This case report describes two instances of hyper-pigmentation induced by prolonged misuse of Betnovate cream, where cessation and appropriate treatment led to significant improvement within 15 days.

This literature review explored the potential therapeutic applications of bee venom, Ficus carica, and Geranium essential oil in treating skin conditions like vitiligo, melasma, and melanoma, concluding these natural products may offer anti-inflammatory, antibacterial, and antioxidant benefits for dermatological care, especially for diabetic patients.

In this study, the authors discuss that while traditional alopecia areata treatments like corticosteroids offer limited efficacy and pose long-term adverse effects, new treatments using janus kinase inhibitors show potential for changing treatment protocols, pending a better understanding of associated adverse drug events.

These guidelines discuss prevention and management strategies for dermatological toxicities but report no new clinical results; they include expert recommendations for conditions like acneiform rash and hand-foot syndrome.

The document concludes that various dermatological treatments and drugs can cause skin reactions and side effects.

Early diagnosis and strong corticosteroids are crucial for managing lymphocytic cicatricial alopecia.

In this study, a patient with Cronkhite-Canada syndrome complicated by severe sepsis and disseminated intravascular coagulation was successfully treated using combined therapies, including recombinant human soluble thrombomodulin, despite the absence of a standard treatment regimen for CCS.

This review discusses current treatment challenges and strategies for managing psoriasis in the scalp, nails, and intertriginous areas, emphasizing the need for effective and well-tolerated long-term options, but reports no new clinical results.

This article reviews lichen planopilaris, a chronic scarring alopecia, and explores recent treatment developments, but it reports no new clinical results.

This review summarizes the cutaneous manifestations of lupus erythematosus, noting both non-specific and disease-specific lesions, and highlights the role of skin biopsies and treatments available for cutaneous LE.

This review analyzed randomized controlled trials on alopecia areata treatment and found that while several treatments showed effectiveness, most studies had limitations affecting their interpretability.

This report discusses the various causes and clinical assessment of madarosis, emphasizing the importance of recognizing and diagnosing associated vision or life-threatening conditions, without presenting new findings.

This review discusses therapies for skin lesions in lupus erythematosus and reports no new clinical results, focusing on defining and managing refractory disease.

In this review, researchers found that TNF-α, IL-17, and JAK inhibitors show the most promise for stabilizing and resolving scarring alopecias, with IL-23 and Interferon Alpha Receptor 1 inhibitors also providing some benefits in managing these hair loss conditions.

This article highlights that early and high-dose corticosteroid therapy, along with immunosuppressive agents, is crucial for managing Vogt-Koyanagi-Harada disease, and emerging biological therapies may benefit refractory cases.

This article discusses the use of mesotherapy in dentistry and reports no new clinical results, emphasizing the need for further research on its applications for oral problems.

This Cochrane Review protocol aims to evaluate the effectiveness and safety of various treatments for alopecia areata through a network meta-analysis, but no specific study findings are reported yet.

This review summarizes current treatments for recalcitrant alopecia areata and recent therapeutic developments targeting specific immunological pathways, reporting no new clinical results.

In this study, clinical case reports of three patients with advanced plaque scalp psoriasis treated with combination therapy including betamethasone dipropionate cream showed symptom relief within 2–3 weeks, highlighting the effectiveness of this treatment approach for managing scalp psoriasis.

This review discusses various treatment options for alopecia areata, focusing on manipulating the immune response around hair follicles, but reports no new clinical results.

In this case report, a 65-year-old woman with lichen planopilaris achieved stabilization of her condition through early recognition and systemic corticosteroid therapy, emphasizing the critical role of coordinated management between primary care and dermatology.

This article discusses the clinical features and treatment options for common types of hair loss in women and reports no new clinical results.

The document concludes that alopecia has various forms, each with specific treatments, but no definitive cure for certain types like CCCA has been proven.

This review outlines the advancements in organ and tissue transplantation since the discovery of the human MHC and reports no new clinical results.

In a study reviewing 291 patients with lichen planopilaris, findings revealed that women were more commonly affected than men, cyclosporine and methotrexate were most effective in achieving remission, and 5-alpha reductase inhibitors and systemic retinoids were particularly beneficial for frontal fibrosing alopecia.

This report describes a Cronkhite-Canada syndrome patient with severe sepsis and disseminated intravascular coagulation successfully treated using combined therapies, including recombinant human soluble thrombomodulin.

This review discusses various drugs that can cause drug-induced acne, noting specific clinical and histopathologic features, but reports no new clinical findings.

This study observed that 70.7% of patients with frontal fibrosing alopecia stabilized with treatment, and patients using 0.3% tacrolimus were more likely to stabilize in 3 months compared to other treatments.

This review discusses recent advances in understanding the cellular, molecular, and genetic factors contributing to lupus erythematosus and reports no new experimental findings.